

Financial news for UTHR dated on 2020-06-10: The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset

Financial news for UTHR dated on 2020-06-05: Liquidia Issues Response To United Therapeutics Suit On Tyvaso Patents

Financial news for UTHR dated on 2020-06-05: United Therapeutics Reports Filed Suit Against Liquidia Related To Infringement Of Tyvaso Patents

Financial news for UTHR dated on 2020-06-05: United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents

Financial news for UTHR dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for UTHR dated on 2020-05-20: The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Financial news for UTHR dated on 2020-05-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for UTHR dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for UTHR dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for UTHR dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for UTHR dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for UTHR dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for UTHR dated on 2020-04-29: United Therapeutics Q1 Adj. EPS \$3.610 Beats \$2.720 Estimate, Sales \$356.300M Beat \$344.330M Estimate

Financial news for UTHR dated on 2020-04-29: Earnings Scheduled For April 29, 2020

Financial news for UTHR dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for UTHR dated on 2020-04-23: United Therapeutics Reports Added Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

Financial news for UTHR dated on 2020-03-31: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for UTHR dated on 2020-03-10: Jefferies Upgrades United Therapeutics to Buy, Raises Price Target to \$123

Financial news for UTHR dated on 2020-02-27: Cowen & Co. Upgrades United Therapeutics to Outperform, Raises Price Target to \$145

Financial news for UTHR dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for UTHR dated on 2020-02-26: United Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results.

Financial news for UTHR dated on 2020-02-26: A Peek Into The Markets: US Stock Futures Drop Ahead Of New-Home Sales Report

Financial news for UTHR dated on 2020-02-26: United Therapeutics Q4 Adj. EPS \$1.96 Misses \$2.65 Estimate, Sales \$211M Miss \$357.77M Estimate

Financial news for UTHR dated on 2020-02-26: Earnings Scheduled For February 26, 2020

Financial news for UTHR dated on 2020-02-24: United Therapeutics shares are trading higher after the company announced its study of Tyvaso met its primary and secondary endpoints. The company also announced FDA clearance related to its unity subcutaneous delivery system for remodulin.

Financial news for UTHR dated on 2020-02-24: United Therapeutics Announces FDA Clearance of its Unity Subcutaneous Delivery System for Remodulin

Financial news for UTHR dated on 2020-02-24: United Therapeutics' Clinical Study of Tyvaso Met its Primary and Secondary Endpoints

Financial news for UTHR dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for UTHR dated on 2020-02-13: Credit Suisse Maintains Outperform on United Therapeutics, Raises Price Target to \$121

Financial news for UTHR dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for UTHR dated on 2020-02-04: United Therapeutics Reports Defeat Of Prelim. Injunction Motion In Litigation With Sandoz, RareGen

Financial news for UTHR dated on 2020-02-03: United Therapeutics Study of Unituxin for Small Cell Lung Cancer Did Not Meet Primary Endpoint

Financial news for UTHR dated on 2020-01-31: JP Morgan Upgrades United Therapeutics to Overweight, Raises Price Target to \$120

Financial news for UTHR dated on 2020-01-29: United Therapeutics Shares Spike To Session High Hearing Sandoz Denied Request For Prelim Injunction Against CO.

Financial news for UTHR dated on 2019-12-13: United Therapeutics 8-K Shows Co. Announced Delay In Potential Launch Of Implantable System For Remodulin From 2020 To 2021

Financial news for UTHR dated on 2019-12-03: Bank Of America Initiates United Therapeutics With Bearing Rating, Cites Unclear Growth Outlook

Financial news for UTHR dated on 2019-11-04: MannKind Reports Receives Second \$12.5M Milestone Payment From United Therapeutics

Financial news for UTHR dated on 2019-10-30: 22 Stocks Moving in Wednesday's Pre-Market Session

Financial news for UTHR dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for UTHR dated on 2019-10-30: United Therapeutics Q3 Adj. EPS \$3.83 Down From \$3.98 YoY, Sales \$401.5M Down From \$412.7M YoY

Financial news for UTHR dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for UTHR dated on 2019-10-21: A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Earnings

Financial news for UTHR dated on 2019-10-21: United Therapeutics' Supplement to its New Drug Application for Orenitram is Accepted by the FDA

Financial news for UTHR dated on 2019-10-21: United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study

Financial news for UTHR dated on 2019-10-10: Respira Therapeutics Highlights Decision By United Therapeutics To Conclude Collaboration With Co. Cites 'strategic prioritization of assets within United Therapeutics' product development portfolio'

Financial news for UTHR dated on 2019-09-12: Correvio Reports FDA Accepted United Therapeutics' Trevyent New Drug Application

Financial news for UTHR dated on 2019-09-11: United Therapeutics Announces FDA Acceptance Of Trevyent NDA For Review

Financial news for UTHR dated on 2019-08-20: iBio Shares Rise 400% Premarket Following Announcement of Agreement with United Therapeutics to Produce Recombinant Human Collagen-based Bioink for 3D Bioprinted Organ Transplants

Financial news for UTHR dated on 2019-08-19: iBio Enters Into Master Services Agreement With Lung Biotechnology For 3D Bioprinted Organ Transplants

Financial news for UTHR dated on 2019-08-01: Benzinga's Top Upgrades, Downgrades For August 1, 2019

Financial news for UTHR dated on 2019-08-01: Ladenburg Thalmann Upgrades United Therapeutics to Buy, Raises Price Target to \$106

Financial news for UTHR dated on 2019-08-01: Jefferies Upgrades United Therapeutics

to Hold, Announces \$90 Price Target

Financial news for UTHR dated on 2019-07-31: United Therapeutics Earlier Reported Q2 Adj. EPS \$3.63 Beats \$2.49 Estimate, Sales \$373.6M Beat \$332.15M Estimate

Financial news for UTHR dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for UTHR dated on 2019-07-31: Earnings Scheduled For July 31, 2019

Financial news for UTHR dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for UTHR dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for UTHR dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for UTHR dated on 2019-07-19: United Therapeutics Option Alert: Aug 16 \$90 Calls at the Ask: 1471 @ \$0.451 vs 106 OI; Earnings 7/31 Before Open [est] Ref=\$75.57

Financial news for UTHR dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for UTHR dated on 2019-07-01: Credit Suisse: United Therapeutics Becoming More Fundamentally Driven

Financial news for UTHR dated on 2019-07-01: United Therapeutics shares are trading higher after Credit Suisse upgraded the stock from Neutral to Outperform.

Financial news for UTHR dated on 2019-07-01: Benzinga's Top Upgrades, Downgrades For July 1, 2019

Financial news for UTHR dated on 2019-07-01: Credit Suisse Upgrades United Therapeutics to Outperform

Financial news for UTHR dated on 2019-06-25: The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

Financial news for UTHR dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for UTHR dated on 2019-05-23: The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut

Financial news for UTHR dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for UTHR dated on 2019-05-17: 10 Biggest Price Target Changes For Friday

Financial news for UTHR dated on 2019-05-17: Benzinga's Top Upgrades, Downgrades For May 17, 2019

Financial news for UTHR dated on 2019-05-17: UBS Upgrades United Therapeutics Corporation - Common Stock to Neutral, Lowers Price Target to \$94

Financial news for UTHR dated on 2019-05-16: The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

Financial news for UTHR dated on 2019-05-14: The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

Financial news for UTHR dated on 2019-05-09: Benzinga's Top Upgrades, Downgrades For May 9, 2019

Financial news for UTHR dated on 2019-05-09: Credit Suisse Upgrades United Therapeutics Corporation - Common Stock to Neutral

Financial news for UTHR dated on 2019-05-07: United Therapeutics And DEKA Announce FDA Clearance Of The Unity Subcutaneous Delivery System For Remodulin

Financial news for UTHR dated on 2019-05-02: 10 Biggest Price Target Changes For Thursday

Financial news for UTHR dated on 2019-05-02: Wedbush Maintains Outperform on United Therapeutics Corporation - Common Stock, Raises Price Target to \$273

Financial news for UTHR dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for UTHR dated on 2019-05-01: United Therapeutics Q1 EPS \$3.58 May Not Compare to \$2.78 Estimate, Sales \$362.6M Beat \$335.43M Estimate

Financial news for UTHR dated on 2019-05-01: Earnings Scheduled For May 1, 2019

Financial news for UTHR dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for UTHR dated on 2019-04-29: United Therapeutics Announces FDA Approval Of XPS And Steen Solution Used To Perform Centralized Ex-Vivo Lung Perfusion Services

Financial news for UTHR dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for UTHR dated on 2019-04-18: United Therapeutics Says Lawsuit Filed by Sandoz and RareGen is 'Meritless'

Financial news for UTHR dated on 2019-04-08: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for UTHR dated on 2019-04-08: UPDATE: United Therapeutics Says Will Discontinue Further Development Of Esuberaprost

Financial news for UTHR dated on 2019-04-08: United Therapeutics Reports BEAT Study Of Esuberaprost Does Not Meet Primary Endpoint

Financial news for UTHR dated on 2019-04-01: MannKind Receives \$12.5M Milestone Payment from United Therapeutics

Financial news for UTHR dated on 2019-03-26: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Financial news for UTHR dated on 2019-03-25: Sandoz Has Exclusively Launched Generic Version Of United Therapeutics Remodulin, Treprostinil

Financial news for UTHR dated on 2019-03-12: United Therapeutics Corporation To Present At Oppenheimer 29th Annual Healthcare Conference

Financial news for UTHR dated on 2019-03-01: Barclays Maintains Underweight on United Therapeutics, Lowers Price Target to \$95

Financial news for UTHR dated on 2019-02-27: United Therapeutics Q4 Adj. EPS \$3.34 Beats \$2.55 Estimate, Sales \$381.4M Beat \$355.83M Estimate

Financial news for UTHR dated on 2019-02-27: Earnings Scheduled For February 27, 2019

Financial news for UTHR dated on 2019-02-21: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for UTHR dated on 2019-01-25: The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

Financial news for UTHR dated on 2019-01-25: Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

Financial news for UTHR dated on 2019-01-15: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for UTHR dated on 2018-11-29: United Therapeutics Reports Health Canada Approved Unituxin For Treatment Of Pediatric High-Risk Neuroblastoma

Financial news for UTHR dated on 2018-11-19: Credit Suisse Maintains Underperform on United Therapeutics, Raises Price Target to \$105

Financial news for UTHR dated on 2018-11-15: UPDATE: Arena Will Grant United

Therapeutics Exclusive Global Rights To Develop, Manufacture, Commercialize Ralinepag; Arena Will Receive Up To \$1.2B

Financial news for UTHR dated on 2018-11-15: Arena Pharma, United Therapeutics Report Global License Deal For Ralinepag

Financial news for UTHR dated on 2018-11-12: CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants

Financial news for UTHR dated on 2018-11-02: JP Morgan Maintains Neutral on United Therapeutics, Raises Price Target to \$126

Financial news for UTHR dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for UTHR dated on 2018-10-31: United Therapeutics Corporation Q3 Adj. EPS \$3.98 Beats \$3.15 Estimate, Sales \$412.7M Beat \$381.27M Estimate

Financial news for UTHR dated on 2018-10-31: Earnings Scheduled For October 31, 2018

Financial news for UTHR dated on 2018-10-22: 10 Hottest Stocks From October 22, 2018

Financial news for UTHR dated on 2018-10-22: CollPlant Holdings shares are moving higher after announced a licensing agreement for 3D bioprinting of solid-organ scaffolds with United Therapeutics. CollPlant will receive \$5M upfront and up to \$15M in milestone payments.

Financial news for UTHR dated on 2018-10-22: CollPlant, United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants; CollPlant to Receive \$5M Upfront, Up to \$15M in Milestones

Financial news for UTHR dated on 2018-10-12: Standpoint Research Upgrades United Therapeutics to Buy

Financial news for UTHR dated on 2018-09-17: Samumed, United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate; Deal Includes \$10M Up-Front Plus Up To \$340M In Developmental Milestones And Up To Low Double-Digit Royalties

Financial news for UTHR dated on 2018-09-05: 55 Biggest Movers From Yesterday

Financial news for UTHR dated on 2018-09-04: Mid-Afternoon Market Update: Gold Prices Fall Below \$1200; MannKind Shares Spike Higher

Financial news for UTHR dated on 2018-09-04: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for UTHR dated on 2018-09-04: Mid-Day Market Update: Ocean Rig Surges On Acquisition News; Seagate Shares Drop

Financial news for UTHR dated on 2018-09-04: Benzinga Pro's 5 Stocks To Watch Today

Financial news for UTHR dated on 2018-09-04: A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Economic Data

Financial news for UTHR dated on 2018-09-04: 'I would have been more impressed had \$UTHR \$MNKD signed a deal to upload Al Mann's consciousness to the cloud.' -STAT's Adam Feuerstein Tweets (2/2)

Financial news for UTHR dated on 2018-09-04: '\$UTHR already sells an inhaled version of trespostinil. It's called Tyvaso. The molecule goes generic soon. Good luck, \$MNKD.' -STAT's Adam Feuerstein Tweets (1/2)

Financial news for UTHR dated on 2018-09-04: United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products; Mannkind Will Receive Upfront Payment of \$45M And Potential Milestones Of Up To \$50M

Financial news for UTHR dated on 2018-08-08: United Therapeutics Announces Settlement of Patent Litigation With Watson Laboratories Relating to Tyvaso

Financial news for UTHR dated on 2018-08-08: 40 Stocks Moving In Wednesday's Pre-Market Session

Financial news for UTHR dated on 2018-08-08: United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint

Financial news for UTHR dated on 2018-08-02: Wedbush Maintains Outperform on United

Therapeutics, Raises Price Target to \$253

Financial news for UTHR dated on 2018-08-01: A Peek Into The Markets: US Stock Futures Mixed Ahead Of Fed Decision

Financial news for UTHR dated on 2018-08-01: United Therapeutics Q2 Adj. EPS \$4.36 Beats \$3.16 Estimate, Sales \$444.5M Beat \$368.58M Estimate

Financial news for UTHR dated on 2018-08-01: Earnings Scheduled For August 1, 2018

Financial news for UTHR dated on 2018-07-31: United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin

Financial news for UTHR dated on 2018-07-31: SteadyMed Shareholders Approve Proposed Acquisition By United Therapeutics; SteadyMed Shareholders To Be Entitled To Receive \$4.46/Share In Cash And One Contractual Contingent Value Right Per Share

Financial news for UTHR dated on 2018-07-20: United Therapeutics, SteadyMed Report Termination Of Waiting Period Under Hart-Scott-Rodino Act

Financial news for UTHR dated on 2018-07-10: Credit Suisse Maintains Neutral on United Therapeutics, Raises Price Target to \$107

Financial news for UTHR dated on 2018-06-12: United Therapeutics, XVIVO Perfusion Announce Collaboration to Reduce Organ Shortage Through Expansion of Organ Evaluation Service

Financial news for UTHR dated on 2018-05-03: Barclays Maintains Underweight on United Therapeutics, Lowers Price Target to \$95.00

Financial news for UTHR dated on 2018-05-03: Credit Suisse Maintains Neutral on United Therapeutics, Lowers Price Target to \$104.00

Financial news for UTHR dated on 2018-05-02: United Therapeutics Reports Q1 2018 EPS of \$3.76 vs \$3.51 Est Revenue of \$389.2M vs \$396.11M Est

Financial news for UTHR dated on 2018-05-02: Earnings Scheduled For May 2, 2018

Financial news for UTHR dated on 2018-05-01: 36 Biggest Movers From Yesterday

Financial news for UTHR dated on 2018-04-30: Merger Monday Makes A Return

Financial news for UTHR dated on 2018-04-30: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Financial Engines Shares Spike Higher

Financial news for UTHR dated on 2018-04-30: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for UTHR dated on 2018-04-30: Mid-Day Market Update: SteadyMed Climbs Following Acquisition News; Cooper Tire & Rubber Shares Slide

Financial news for UTHR dated on 2018-04-30: Mid-Morning Market Update: Markets Open Higher; Sprint And T-Mobile To Merge In \$26 Billion Deal

Financial news for UTHR dated on 2018-04-30: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for UTHR dated on 2018-04-30: United Therapeutics to Acquire SteadyMed for \$4.46/Share Cash and an Additional \$2.63/Share Cash if a Milestone is Met

Financial news for UTHR dated on 2018-04-30: United Therapeutics to Acquire SteadyMed for \$4.46/Share in Cash at Closing

Financial news for UTHR dated on 2018-04-04: 35 Biggest Movers From Yesterday

Financial news for UTHR dated on 2018-04-03: United Therapeutics Has Limited Downside Below \$95 Level, Credit Suisse Says In Upgrade

Financial news for UTHR dated on 2018-04-03: 26 Stocks Moving In Tuesday's Mid-Day Session

Financial news for UTHR dated on 2018-04-03: Benzinga's Top Upgrades, Downgrades For April 3, 2018

Financial news for UTHR dated on 2018-04-03: Credit Suisse Upgrades United Therapeutics to Neutral

Financial news for UTHR dated on 2018-02-22: Credit Suisse Maintains Underperform on United Therapeutics, Lowers price target to \$115.00

Financial news for UTHR dated on 2018-02-21: A Peek Into The Markets: U.S. Stock Futures Fall; All Eyes On Fed Minutes

Financial news for UTHR dated on 2018-02-21: United Therapeutics Reports Q4 EPS \$3.89 vs \$3.89 Est., Sales \$464.7M vs \$421M Est.

Financial news for UTHR dated on 2018-02-21: Earnings Scheduled For February 21, 2018

Financial news for UTHR dated on 2018-02-16: United Therapeutics Shares Appear Unaffected Fri. Following Late Thurs. News Of Settlement Of Patent Litigation With Actavis Related To Orenitram; Co. Granted Actavis License To Manufacture, Commercialize Generic Version

Financial news for UTHR dated on 2018-01-03: A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Fed Minutes

Financial news for UTHR dated on 2018-01-03: Corsair Pharma, United Therapeutics Enter Into Strategic Collaboration to Advance Novel Treprostinil Prodrugs

Financial news for UTHR dated on 2017-12-27: 5 Biggest Price Target Changes For Wednesday

Financial news for UTHR dated on 2017-12-20: United Therapeutics Has Settled US Kickback Investigation For \$210M

Financial news for UTHR dated on 2017-11-20: United Therapeutics is Grated Pediatric Exclusivity for Adcirca Through May 21, 2018 by the FDA

Financial news for UTHR dated on 2017-10-25: United Therapeutics Q3 Adj. EPS \$4.69 vs \$3.87 Est., Sales \$445.5M vs \$426.4M Est.

Financial news for UTHR dated on 2017-10-25: Earnings Scheduled For October 25, 2017

Financial news for UTHR dated on 2017-10-23: United Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso Inhalation System

Financial news for UTHR dated on 2017-09-08: 22 Biggest Mid-Day Losers For Friday

Financial news for UTHR dated on 2017-09-01: Oppenheimer Presents New Menu Of Top Picks

Financial news for UTHR dated on 2017-08-07: Wall Street's M&A Chatter From August 4-7: Acadia Pharma, United Technologies-Rockwell Collins, United Therapeutics

Financial news for UTHR dated on 2017-08-04: JP Morgan Out Negative On United Therapeutics, Says Near Term Deal Is Highly Unlikely; Is Referring to Evening Standard Report That Suggested GSK, Gilead, or Novartis Would Be Looking At A Possible Acquisition Of United Therapeutics

Financial news for UTHR dated on 2017-08-04: 20 Biggest Mid-Day Gainers For Friday

Financial news for UTHR dated on 2017-08-04: United Therapeutics Shares Up 7.7% On M&A Chatter; GSK, Gilead, Novartis Said To Be Possibly Considering Deal For Co.

Financial news for UTHR dated on 2017-08-04: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for UTHR dated on 2017-08-04: UK Evening Standard Reports GSK, Gilead, Novartis Could Pay Up to \$200/Share for United Therapeutics

Financial news for UTHR dated on 2017-07-28: UPDATE: United Therapeutics Says Expects To Vigorously Enforce IP Rights Related To Tyvaso

Financial news for UTHR dated on 2017-07-28: 8-K From United Therapeutics Shows Co. Filed With District Court Deal With Watson To Stay Case Until PTAB Resolves Watson's Petitions For IPR

Financial news for UTHR dated on 2017-07-27: United Therapeutics Reports Q2 Adj. EPS \$4.37 vs \$3.61 Est., Sales \$444.6M vs \$391.5M Est.

Financial news for UTHR dated on 2017-07-27: Earnings Scheduled For July 27, 2017

Financial news for UTHR dated on 2017-06-29: Oppenheimer Analysts Release 28 Best Ideas List

Financial news for UTHR dated on 2017-06-28: Companies Holding Shareholder Meetings Today Include: AC Immune, AIG, Signet Jewelers, Trans World Entertainment, And United Therapeutics

Financial news for UTHR dated on 2017-06-09: Kansas City Southern, Snap, United Therapeutics: Fast Money Picks For June 9

Financial news for UTHR dated on 2017-04-26: 3D Systems, United Therapeutics Announce Bioprinting Agreement

Financial news for UTHR dated on 2017-04-26: United Therapeutics Q1 EPS \$3.61 vs \$3.54 Est, Sales \$370.5M vs \$398.2M Est

Financial news for UTHR dated on 2017-04-12: Respira Therapeutics Enters Into Strategic Partnership With United Therapeutics For Development, Exclusive License Of Respira's RT234

Financial news for UTHR dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for UTHR dated on 2017-04-03: 12 Biggest Mid-Day Losers For Monday

Financial news for UTHR dated on 2017-04-03: United Therapeutics Falls After US Launch Of RemoSynch Gets Delayed

Financial news for UTHR dated on 2017-04-03: UPDATE: Oppenheimer Says 'We Stay Bullish' on United Therapeutics

Financial news for UTHR dated on 2017-04-03: Hearing Oppenheimer Commenting on United Therapeutics: 'RemoSynch Pump Delays Jars Sentiment; Numbers Don't Change'

Financial news for UTHR dated on 2017-04-03: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for UTHR dated on 2017-04-03: United Therapeutics Says the US Launch of RemoSynch will be Delayed due to Regulatory Delays

Financial news for UTHR dated on 2017-03-31: SteadyMed Reports Received Favorable Ruling in IPR Against United Therapeutics Patent

Financial news for UTHR dated on 2017-03-31: UPDATE: United Therapeutics is Evaluating Options, Including 'possibility of immediately exercising its right of appeal to the U.S. Court of Appeals for the Federal Circuit or first requesting a rehearing before the PTAB'

Financial news for UTHR dated on 2017-03-31: UPDATE: United Therapeutics Says PTAB Found All Claims of '393 Patent Are Not Patentable

Financial news for UTHR dated on 2017-03-31: United Therapeutics Reports Decision from Patent Trial, Appeal Board, Issuance of New Patents

Financial news for UTHR dated on 2017-03-31: United Therapeutics Sells off to Low of \$133.07 on Volume

Financial news for UTHR dated on 2017-03-30: Benzinga's Top Upgrades, Downgrades For March 30, 2017

Financial news for UTHR dated on 2017-03-30: UBS Initiates Coverage On United Therapeutics With Sell, Announces \$112 Price Target

Financial news for UTHR dated on 2017-03-16: 18 Biggest Mid-Day Losers For Thursday

Financial news for UTHR dated on 2017-03-16: Benzinga's Top Upgrades, Downgrades For March 16, 2017

Financial news for UTHR dated on 2017-03-16: Credit Suisse Initiates Coverage On United Therapeutics With Underperform

Financial news for UTHR dated on 2017-03-09: Northwell Health, United Therapeutics Announce Strategic Partnership to Advance Bioelectronic Medicine and Cell Therapy

Financial news for UTHR dated on 2017-03-06: Jefferies Downgrades United Therapeutics To Underperform, Maintains \$116 Price Target

Financial news for UTHR dated on 2017-02-22: United Therapeutics Q4 EPS \$4.12 vs \$3.61 Est, Revenue \$409.0M vs \$415.5M Est, May Not Compare

Financial news for UTHR dated on 2017-02-22: Earnings Scheduled For February 22, 2017

Financial news for UTHR dated on 2017-02-07: Your Guide To 2017's Emerging Pharmaceuticals Catalysts

Financial news for UTHR dated on 2017-01-19: Standpoint Research Downgrades United

Therapeutics to Hold

Financial news for UTHR dated on 2017-01-03: 13 Emerging Biotechs With Catalysts In 2017

Financial news for UTHR dated on 2016-12-30: United Therapeutics Spikes to High on Volume

Financial news for UTHR dated on 2016-12-19: Here's Oppenheimer's List Of The 29 Best Stocks For 2017

Financial news for UTHR dated on 2016-12-14: Oppenheimer Initiates Coverage On United Therapeutics at Outperform, Announces \$160.00 Target

Financial news for UTHR dated on 2016-11-29: Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Financial news for UTHR dated on 2016-11-29: 7 Biggest Price Target Changes For Tuesday

Financial news for UTHR dated on 2016-11-29: Barclays Downgrades United Therapeutics to Underweight

Financial news for UTHR dated on 2016-11-02: 10 Stocks That Rallied Four Days, Then Sold Off Yesterday

Financial news for UTHR dated on 2016-10-28: 7 Biggest Price Target Changes For Friday

Financial news for UTHR dated on 2016-10-28: Benzinga's Top Upgrades

Financial news for UTHR dated on 2016-10-28: 5 Stocks That Rallied Three Days On Increasing Volume

Financial news for UTHR dated on 2016-10-28: Ladenburg Thalmann Upgrades United Therapeutics Corporation - Common Stock to Buy, Raises to \$138.00

Financial news for UTHR dated on 2016-10-28: 20 Stocks That Rallied Three Days On No News

Financial news for UTHR dated on 2016-10-27: United Therapeutics Q3 EPS \$4.36 vs \$3.34 Est, Revenue \$408.2M vs \$402.4M Est

Financial news for UTHR dated on 2016-10-21: 6 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for UTHR dated on 2016-10-11: 10 LGBT CEOs Who Weren't Afraid To Come Out

Financial news for UTHR dated on 2016-09-08: 5 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for UTHR dated on 2016-08-22: United Therapeutics Hurt By Competitive Pressure

Financial news for UTHR dated on 2016-07-28: United Therapeutics Reports Q2 Adj. EPS \$4.55 vs \$2.56 in Same Qtr. Last Year, Sales \$412.6M vs \$395M Est.

Financial news for UTHR dated on 2016-06-15: H.C. Wainwright Downgrades United Therapeutics To Neutral

Financial news for UTHR dated on 2016-06-15: 7 Largest Price Target Changes For Wednesday

Financial news for UTHR dated on 2016-06-15: Benzinga's Top Downgrades

Financial news for UTHR dated on 2016-06-15: H.C. Wainwright Downgrades United Therapeutics to Neutral, Lowers PT to \$95.00

Financial news for UTHR dated on 2016-05-24: Benzinga's Top Downgrades

Financial news for UTHR dated on 2016-05-24: Argus Downgrades United Therapeutics To Hold, Cites 'Challenging Outlook'

Financial news for UTHR dated on 2016-05-24: Argus Research Downgrades United Therapeutics to Hold

Financial news for UTHR dated on 2016-04-29: Ladenburg Thalmann Downgrades United Therapeutics to Neutral

Financial news for UTHR dated on 2016-04-28: Stocks Hitting 52-Week Lows

Financial news for UTHR dated on 2016-04-28: United Therapeutics Reports Q1 Adj. EPS \$3.02 vs \$3.21 Est., Sales \$369M vs \$397.4M Est.

Financial news for UTHR dated on 2016-04-28: United Therapeutics Announces Roger Jeffs, Ph.D. has Stepped Down as President and Co-CEO, Michael Benkowitz Named President, COO

Financial news for UTHR dated on 2016-04-11: SteadyMed Announces USPTO Initiating Inter Partes Review Against United Therapeutics

Financial news for UTHR dated on 2016-03-24: United Therapeutics Says Informed by Medtronic that FDA issued Response Letter Indicating PMA is Not Approvable; UTHR Expects FDA Action in 2016 Regarding NDA Seeking FDA Approval of New Labeling for Remodulin

Financial news for UTHR dated on 2016-02-26: Barclays Maintains Equal-weight on United Therapeutics, Lowers PT to \$145.00

Financial news for UTHR dated on 2016-02-25: United Therapeutics Reports Q4 EPS \$2.10 Vs Est \$2.55, Sales \$405M Vs Est \$388.29M

Financial news for UTHR dated on 2016-02-25: Earnings Scheduled For February 25, 2016

Financial news for UTHR dated on 2016-02-10: Standpoint Research Upgrades United Therapeutics to Buy, Announces \$148.00 PT

Financial news for UTHR dated on 2016-01-19: Teva Pharma and United Therapeutics Announce Settlement of Remodulin Patents, Teva Granted Non-Exclusive License to Manufacture Generic in US

Financial news for UTHR dated on 2016-01-02: Every Biotech Catalyst Wedbush Is Watching In 2016

Financial news for UTHR dated on 2015-10-27: Mid-Morning Market Update: Markets Down; Ford Earnings Miss Views

Financial news for UTHR dated on 2015-10-27: United Therapeutics Q3 EPS \$3.55 vs \$2.36 est, Revenue \$386M vs \$363.5M est

Financial news for UTHR dated on 2015-10-19: Cowen: In Biotech Earnings We Trust

Financial news for UTHR dated on 2015-10-15: United Therapeutics Announces Additional \$500 M Share Buyback Program

Financial news for UTHR dated on 2015-09-30: United Therapeutics Reports Settlement of Patent Litigation with Sandoz

Financial news for UTHR dated on 2015-09-22: Synthetic Genomics Inc. Increases Collaborative Research and Development Agreement with Lung Biotechnology PBC, a Subsidiary of United Therapeutics Corporation; Lung Biotech Makes Additional \$50M Equity Inv. In SGI

Financial news for UTHR dated on 2015-08-31: Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

Financial news for UTHR dated on 2015-08-19: Wedbush Maintains Outperform on United Therapeutics, Raises PT to \$244.00

Financial news for UTHR dated on 2015-08-19: Benzinga's M&A Chatter for Wednesday August 19, 2015

Financial news for UTHR dated on 2015-08-19: United Therapeutics To Sell Priority Review Voucher To AbbVie For \$350M

Financial news for UTHR dated on 2015-08-17: Wedbush's Moussatos Reiterates Outperform, \$209 Price Target on United Therapeutics Following Unituxin Being Granted Market Authorization by EC

Financial news for UTHR dated on 2015-08-17: US Stock Futures Flat Ahead Of Housing Data

Financial news for UTHR dated on 2015-08-17: EC Grants Marketing Authorization for Unituxin for Treatment of Paediatric High-Risk Neuroblastoma

Financial news for UTHR dated on 2015-07-28: United Therapeutics Q2 EPS \$2.55 vs \$2.31 est, Revenue \$347.2M vs \$360M est

Financial news for UTHR dated on 2015-07-21: New Alzheimer's Trials Could Produce The Most Important Drugs In History

Financial news for UTHR dated on 2015-06-19: United Therapeutics CEO Jeffs Acquires 10,000 Shares @\$51.37/Share -Form 4

Financial news for UTHR dated on 2015-06-15: United Therapeutics Corporation Receives Paragraph IV Notice Letter for Tyvaso

Financial news for UTHR dated on 2015-05-29: Who's The Next Big Pharma Acquisition?

Financial news for UTHR dated on 2015-05-22: EMA Recommends Approval of United Therapeutics Neuroblastoma Drug Unituxin

Financial news for UTHR dated on 2015-05-05: Apple's Angela Ahrendts Is Nation's Best-Paid Female Executive

Financial news for UTHR dated on 2015-04-28: Earnings Scheduled For April 28, 2015

Financial news for UTHR dated on 2015-04-07: Biotech: Anatomy Of An Investing Mania?

Financial news for UTHR dated on 2015-03-17: 5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for UTHR dated on 2015-03-12: Argus Research Upgrades United Therapeutics to Buy

Financial news for UTHR dated on 2015-03-10: FDA Approves United Therapeutics' Unituxin For Treatment Of High Risk Neuroblastoma

Financial news for UTHR dated on 2015-03-10: Shares of United Therapeutics Bounce from Session Lows as Earlier Heard Report FDA Has Approved Co.'s Unituxin

Financial news for UTHR dated on 2015-02-24: United Therapeutics Q4 EPS \$3.21 vs \$2.05, May Not Compare, Revenue \$346.4M vs \$336.2M

Financial news for UTHR dated on 2015-02-24: Earnings Scheduled For February 24, 2015

Financial news for UTHR dated on 2015-01-13: What Investors Are Looking At In The Stem Cell Sector

Financial news for UTHR dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for UTHR dated on 2015-01-11: Credit Suisse's 4 Healthcare Stocks To Avoid

Financial news for UTHR dated on 2015-01-06: UPDATE: Barclays Initiates Coverage On United Therapeutics

Financial news for UTHR dated on 2015-01-06: Barclays Initiates Coverage on United Therapeutics at Equal-weight, Announces \$135.00 PT

Financial news for UTHR dated on 2015-01-05: UPDATE: BTIG Initiates Coverage On United Therapeutics

Financial news for UTHR dated on 2015-01-05: BTIG Research Initiates Coverage on United Therapeutics at Neutral

Financial news for UTHR dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for UTHR dated on 2014-12-31: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for UTHR dated on 2014-12-31: United Therapeutics Announces Agreement for New Remodulin Delivery System; Terms Not Disclosed

Financial news for UTHR dated on 2014-12-24: United Therapeutics Submits Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin

Financial news for UTHR dated on 2014-12-17: United Therapeutics Names Roger Jeffs, Ph.D. President and Co-CEO

Financial news for UTHR dated on 2014-12-11: Benzinga's Top Downgrades

Financial news for UTHR dated on 2014-12-11: Credit Suisse Downgrades United Therapeutics To Underperform

Financial news for UTHR dated on 2014-12-11: US Stock Futures Edge Higher Ahead Of Retail Sales, Jobless Claims Data

Financial news for UTHR dated on 2014-12-11: Credit Suisse Downgrades United Therapeutics Corporation to Underperform, Raises PT to \$120.00

Financial news for UTHR dated on 2014-10-30: Apple's Tim Cook And 5 Other Notable LGBT CEOs

Financial news for UTHR dated on 2014-10-28: Worst Performing Industries For October 28, 2014

Financial news for UTHR dated on 2014-10-28: United Therapeutics Corporation Reports Q3 EPS of \$3.91 vs \$1.97 Est; Revenue of \$330.0M vs \$335.08M Est

Financial news for UTHR dated on 2014-10-28: Earnings Scheduled For October 28, 2014

Financial news for UTHR dated on 2014-10-15: Standpoint Research Upgrades United Therapeutics Corporation to Buy, Announces \$144.00 PT

Financial news for UTHR dated on 2014-09-22: Standpoint Research Downgrades United Therapeutics Corporation to Hold

Financial news for UTHR dated on 2014-09-17: Stocks Hitting 52-Week Highs

Financial news for UTHR dated on 2014-09-17: Axsome Therapeutics Announces Appointments to Its Board of Directors

Financial news for UTHR dated on 2014-09-16: Pluristem Evaluating Strategic Opportunities in Japan

Financial news for UTHR dated on 2014-09-08: United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's PLX-PAD Cells for Treatment of PAH

Financial news for UTHR dated on 2014-08-29: Cowen Raises PT on United Therapeutics from \$130 to \$140 with Outperform Rating

Financial news for UTHR dated on 2014-08-29: Wedbush Lifts Target on United Therapeutics Corporation from \$133 to \$141

Financial news for UTHR dated on 2014-08-29: UPDATE: United Therapeutics Release Shows Judge Found Patent Expiring '17 'Both Valid and Enforceable Against Sandoz,' Found '29 Patent 'Vaild But Would Not Be Infringed by Sandoz'

Financial news for UTHR dated on 2014-08-29: United Therapeutics Announces NJ District Court Rule In Favor of Co. in Remodulin Patent Case

Financial news for UTHR dated on 2014-08-29: United Therapeutics Gets Favorable Ruling, Shares Flying Higher

Financial news for UTHR dated on 2014-08-29: ISI Analyst Suggesting United Therapeutics Ruling Places a Large Overhang Behind the Co., Recommends Investors Consider Owning Shares on Potential for Strong Oral Orenitram Sales

Financial news for UTHR dated on 2014-08-29: Hearing Positive Court Ruling for United Therapeutics

Financial news for UTHR dated on 2014-08-29: United Therapeutics Spikes Higher

Financial news for UTHR dated on 2014-07-29: United Therapeutics Reports Q2 Adjusted EPS of \$2.30 vs \$1.75 Est; Revenue of \$322.80M vs \$308.04M Est

Financial news for UTHR dated on 2014-07-29: Earnings Scheduled For July 29, 2014

Financial news for UTHR dated on 2014-06-27: United Therapeutics Board Approves Additional \$500M Share-Buyback Program

Financial news for UTHR dated on 2014-06-16: Credit Suisse Upgrades United Therapeutics Corporation to Outperform

Financial news for UTHR dated on 2014-05-20: Supernus Revives \$2M Milestone for United Therapeutics Orenitram Launch

Financial news for UTHR dated on 2014-05-06: Synthetic Genomics Signs Collaborative Agreement with United Therapeutics Subsidiary Lung Biotechnology

Financial news for UTHR dated on 2014-04-29: United Therapeutics Reports Q1 Adjusted EPS of \$1.77 vs \$1.65 Est; Revenue of \$289.40M vs \$300.14M Est

Financial news for UTHR dated on 2014-04-29: Earnings Scheduled For April 29, 2014

Financial news for UTHR dated on 2014-04-07: Standpoint Research Upgrades United Therapeutics Corporation to Buy

Financial news for UTHR dated on 2014-03-26: Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin

Financial news for UTHR dated on 2014-03-11: Hearing Deutsche Bank Negative on United Therapeutics

Financial news for UTHR dated on 2014-02-28: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

Financial news for UTHR dated on 2014-02-25: United Therapeutics Reports Q4 Adjusted EPS of \$3.19 vs \$1.51 Est; Revenue of \$289.0M vs \$295.43M Est

Financial news for UTHR dated on 2014-02-25: Earnings Scheduled For February 25, 2014

Financial news for UTHR dated on 2013-12-24: The Five Best Performing Stocks From Monday

Financial news for UTHR dated on 2013-12-23: Supernus Confirms FDA Approval of United Therapeutics' Orenitram

Financial news for UTHR dated on 2013-12-23: Ladenburg Thalmann Upgrades United Therapeutics Corporation to Buy

Financial news for UTHR dated on 2013-12-23: United Therapeutic Shares Rocketing Higher Following FDA Approval of Orenitram, JP Morgan Upgrade

Financial news for UTHR dated on 2013-12-23: Benzinga's Volume Movers

Financial news for UTHR dated on 2013-12-23: Stocks Hitting 52-Week Highs

Financial news for UTHR dated on 2013-12-23: Mid-Morning Market Update: Markets Surge; Seagate To Acquire Xyratex For \$374M

Financial news for UTHR dated on 2013-12-23: Morning Market Movers

Financial news for UTHR dated on 2013-12-23: UPDATE: United Therapeutics Announces FDA Approval of OrenitramExtended-Release Tablets forTreatment of Pulmonary Arterial Hypertension

Financial news for UTHR dated on 2013-12-23: Benzinga's Top Upgrades

Financial news for UTHR dated on 2013-12-23: JP Morgan Upgrades United Therapeutics Corporation to Neutral, Raises PT to \$90.00

Financial news for UTHR dated on 2013-12-10: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

Financial news for UTHR dated on 2013-12-09: US Stock Futures Mixed; Japan Posts Current Account Deficit

Financial news for UTHR dated on 2013-12-09: United Therapeutics Receives Subpoena from Office of Inspector General

Financial news for UTHR dated on 2013-11-07: Stocks Hitting 52-Week Highs

Financial news for UTHR dated on 2013-11-07: Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates

Financial news for UTHR dated on 2013-10-29: US Stock Futures Flat Ahead Of Fed

Financial news for UTHR dated on 2013-10-29: UPDATE: United Therapeutics Posts Weaker-Than-Expected Q3 Earnings

Financial news for UTHR dated on 2013-10-29: United Therapeutics Reports Q3 EPS of \$2.98 Which May Not Compare \$1.59 Est; Revenue of \$302.20M Which May Not Compare \$279.02M Est

Financial news for UTHR dated on 2013-10-07: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin

Financial news for UTHR dated on 2013-09-26: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

Financial news for UTHR dated on 2013-09-11: United Therapeutics Reports FDA Acceptance of Second Submission of Oral Treprostinil NDA

Financial news for UTHR dated on 2013-07-30: Standpoint Research Downgrades United Therapeutics Corporation to Hold

Financial news for UTHR dated on 2013-07-26: BMO Capital Maintains Market Perform on United Therapeutics Corporation, Raises PT to \$68.00

Financial news for UTHR dated on 2013-07-25: United Therapeutics Corporation Reports Q2 EPS of \$3.11 vs \$1.47 Est; Revenue of \$280.60M vs \$250.17M Est

Financial news for UTHR dated on 2013-07-15: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin

Financial news for UTHR dated on 2013-06-20: Standpoint Upgrades United Therapeutics from Hold to Buy

Financial news for UTHR dated on 2013-06-17: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest ROA

Financial news for UTHR dated on 2013-05-24: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

Financial news for UTHR dated on 2013-05-15: United Therapeutics Shares Sink as Standpoint Downgrades to Hold

Financial news for UTHR dated on 2013-04-25: United Therapeutics Corporation Reports Q1 Ex-Charges EPS of \$2.46 vs \$1.47 Est; Revenue of \$245.10M vs \$241.14M Est

Financial news for UTHR dated on 2013-03-26: 13 Drugs Pending FDA Approval in 2013

Financial news for UTHR dated on 2013-03-25: Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit

Financial news for UTHR dated on 2013-03-25: Benzinga's Top Pre-Market Losers

Financial news for UTHR dated on 2013-03-25: United Therapeutics Receives Second CRL from FDA for Oral Treprostinil NDA

Financial news for UTHR dated on 2013-03-12: Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest EPS

Financial news for UTHR dated on 2013-02-27: UPDATE: Deutsche Bank Reiterates Hold Rating, Raises PT on United Therapeutics Corporation on Cut Expense Numbers

Financial news for UTHR dated on 2013-02-27: Deutsche Bank Maintains Hold on United Therapeutics Corporation, Raises PT to \$56.00

Financial news for UTHR dated on 2013-02-26: Brean Capital Downgrades United Therapeutics Corporation to Hold

Financial news for UTHR dated on 2013-02-26: United Therapeutics Spikes Lower

Financial news for UTHR dated on 2013-02-26: United Therapeutics Corporation Reports Q4 EPS of \$2.50 vs \$1.25 Est

Financial news for UTHR dated on 2013-02-26: Earnings Scheduled For February 26, 2013

Financial news for UTHR dated on 2013-02-04: Standpoint Research Upgrades United Therapeutics Corporation to Buy

Financial news for UTHR dated on 2013-02-04: A Peek Into The Market Before The Trading Starts

Financial news for UTHR dated on 2013-02-04: United Therapeutics Authorizes Additional \$420M Share Buyback

Financial news for UTHR dated on 2013-01-23: Guggenheim Securities Initiates Coverage on United Therapeutics Corporation at Neutral

Financial news for UTHR dated on 2013-01-08: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash

Financial news for UTHR dated on 2012-12-13: UPDATE: Goldman Sachs Downgrades United Therapeutics Corporation to Sell; Upside Capped

Financial news for UTHR dated on 2012-12-13: Benzinga's Top Downgrades

Financial news for UTHR dated on 2012-12-13: Goldman Sachs Downgrades United Therapeutics Corporation to Sell, Maintains \$50.00 PT

Financial news for UTHR dated on 2012-11-01: United Therapeutics Reports Q3 EPS \$1.46 vs \$1.26 Est; Revenues \$242.5M vs \$227.63M Est

Financial news for UTHR dated on 2012-10-24: Benzinga Mid-Morning Market Update

Financial news for UTHR dated on 2012-10-24: BMO Capital Markets Downgrades United Therapeutics from Outperform to Market Perform, Lowers PT from \$63 to \$50

Financial news for UTHR dated on 2012-10-24: UPDATE: JP Morgan Downgrades United Therapeutics to Underweight

Financial news for UTHR dated on 2012-10-24: JP Morgan Downgrades United Therapeutics from Neutral to Underweight, Lowers PT from \$50 to \$40

Financial news for UTHR dated on 2012-10-23: United Therapeutics Announces Receipt Of Complete Response Letter For Oral Treprostinil NDA

Financial news for UTHR dated on 2012-07-26: Deutsche Bank Maintains United Therapeutics at Hold, Raises PT from \$53 to \$58

Financial news for UTHR dated on 2012-07-26: Deutsche Bank Maintains United Therapeutics at Hold, Raises PT from \$53 to \$58

Financial news for UTHR dated on 2012-07-26: United Therapeutics Reports Q2 EPS \$2.37 May Not Compare vs \$1.12 Est; Revenues \$225.6M vs \$213.33M Est

Financial news for UTHR dated on 2012-07-24: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Lowest PEG Ratio

Financial news for UTHR dated on 2012-06-27: Financial Breakfast: Morning News Summary for June 27, 2012

Financial news for UTHR dated on 2012-06-27: A Peek Into The Market Before The Trading Starts

Financial news for UTHR dated on 2012-06-27: United Therapeutics Announces Additional \$100 Million Share Repurchase Program

Financial news for UTHR dated on 2012-06-26: Medtronic, Snyder's-Lance and Other Stocks Insiders Are Buying

Financial news for UTHR dated on 2012-06-22: United Therapeutics: Meeting Unmet Clinical Needs

Financial news for UTHR dated on 2012-04-30: UPDATE: Ladenburg Thalmann Lowers United Therapeutics' PT

Financial news for UTHR dated on 2012-04-30: Ladenburg Thalmann Maintains United Therapeutics at Buy, Lowers PT from \$61 to \$58

Financial news for UTHR dated on 2012-04-27: UPDATE: Canaccord Downgrades United Therapeutics; Lowers PT

Financial news for UTHR dated on 2012-04-27: Canaccord Downgrades United Therapeutics from Buy to Hold, Lowers PT from \$56 to \$44

Financial news for UTHR dated on 2012-04-26: United Therapeutics Reports Q1 EPS \$2.08 May Not Compare vs \$0.93 Est; Revenues \$204.2M vs \$203.78M Est

Financial news for UTHR dated on 2012-04-24: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest ROE

Financial news for UTHR dated on 2012-04-12: Benzinga's Top Downgrades

Financial news for UTHR dated on 2012-03-26: Canaccord Initiates Coverage on United Therapeutics at Buy, Announces PT of \$56

Financial news for UTHR dated on 2012-03-15: A Peek Into The Market Before The Trading Starts

Financial news for UTHR dated on 2012-03-15: United Therapeutics Files Lawsuit Against Sandoz for Infringement of Remodulin Patents

Financial news for UTHR dated on 2012-02-21: Oral Treprostinil New Drug Application Accepted by FDA for Review

Financial news for UTHR dated on 2012-02-14: Brean Murray Carret & Co. Maintains United Therapeutics at Buy, Raises PT from \$55 to \$57

Financial news for UTHR dated on 2012-02-14: Deutsche Bank: United Therapeutics' Light Revenue Likely Due to Seasonality

Financial news for UTHR dated on 2012-02-14: Collins Stewart: United Therapeutics Reiterates FY12/FY13 Revenue Guidance, Despite 4Q11 Miss

Financial news for UTHR dated on 2012-02-14: United Therapeutics Reports Q4 EPS \$0.79 vs \$0.87 Est; Revenues \$195.20M vs \$204.81M Est

Financial news for UTHR dated on 2012-02-06: United Therapeutics Receives Paragraph IV Notice Letter for Remodulin

Financial news for UTHR dated on 2012-01-24: United Therapeutics Spiking Lower on FDA Notice Regarding Generic Remodulin

Financial news for UTHR dated on 2012-01-24: United Therapeutics Spiking Lower on Heavy Volume

Financial news for UTHR dated on 2012-01-13: United Therapeutics Spiking Lower on Heavy Volume

Financial news for UTHR dated on 2011-12-27: Eight Healthcare Stocks Insiders Are Bullish About

Financial news for UTHR dated on 2011-12-27: Wedbush Maintains Outperform on United Therapeutics Ahead of FDA Vote

Financial news for UTHR dated on 2011-12-27: JP Morgan Neutral on United Therapeutics After IV Remodulin Approval

Financial news for UTHR dated on 2011-12-27: Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union

Financial news for UTHR dated on 2011-11-22: Pluristem Therapeutics' CEO Letter to Shareholders

Financial news for UTHR dated on 2011-11-22: Pluristem Therapeutics' CEO Letter to Shareholders: "Current Data Suggest that Approx 20% of CLI patients will Die Within the first 6-12 Months"

Financial news for UTHR dated on 2011-10-27: United Therapeutics Reports Q3 EPS \$1.65 May Not Compare \$0.73 Est; Revenues \$201.7M vs \$194.77M Est

Financial news for UTHR dated on 2011-10-12: United Therapeutics Prices Private Offering of Convertible Senior Notes and Announces Concurrent Exercise of Overallotment Option

Financial news for UTHR dated on 2011-10-11: ISI Group Comments On United Therapeutics' \$212M Share Re-Purchase Announcement

Financial news for UTHR dated on 2011-10-11: United Therapeutics Announces Proposed Private Offering of \$210M of Convertible Senior Notes; Authorizes of Stock Repurchase Program

Financial news for UTHR dated on 2011-10-10: United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to \$45 Million to Support Glycobiology Antiviral Program

Financial news for UTHR dated on 2011-10-07: Notable Call Options Activity in United Therapeutics

Financial news for UTHR dated on 2011-09-26: ISI Group Defending United Therapeutics

Financial news for UTHR dated on 2011-09-16: Pluristem Therapeutics CEO Letter to Shareholders

Financial news for UTHR dated on 2011-09-15: UPDATE: Goldman Sachs Upgrades Onyx Pharmaceuticals to Buy

Financial news for UTHR dated on 2011-09-15: UPDATE: Goldman Sachs Downgrades United Therapeutics to Neutral

Financial news for UTHR dated on 2011-09-15: Goldman Sachs Downgrades United Therapeutics, Removes From CL-Buy List

Financial news for UTHR dated on 2011-08-25: UPDATE: Ladenburg Thalmann Lowers PT on

United Therapeutics

Financial news for UTHR dated on 2011-08-25: Ladenburg Thalmann Lowers PT On United Therapeutics To \$61

Financial news for UTHR dated on 2011-08-25: UPDATE: Auriga Downgrades United Therapeutics to Hold

Financial news for UTHR dated on 2011-08-25: UPDATE: Goldman Sachs Lowers PT on United Therapeutics to \$52

Financial news for UTHR dated on 2011-08-25: Financial Breakfast for August 25, 2011

Financial news for UTHR dated on 2011-08-25: Benzinga's Top Downgrades

Financial news for UTHR dated on 2011-08-25: Auriga Downgrades United Therapeutics To Hold, \$45 PT

Financial news for UTHR dated on 2011-08-25: Goldman Sachs Lowers PT On United Therapeutics To \$52

Financial news for UTHR dated on 2011-08-24: Morning Market Losers

Financial news for UTHR dated on 2011-08-24: UPDATE: Wunderlich Initiates Coverage on Edwards Lifesciences

Financial news for UTHR dated on 2011-08-24: UPDATE: J.P. Morgan Downgrades United Therapeutics to Neutral

Financial news for UTHR dated on 2011-08-24: Pre-Market Losers; United Therapeutics Down 21%

Financial news for UTHR dated on 2011-08-24: Deutsche Bank Downgrades United Therapeutics To Hold

Financial news for UTHR dated on 2011-08-24: JP Morgan Downgrades UTHR To Neutral, Lowers PT To \$55

Financial news for UTHR dated on 2011-08-24: Benzinga's Top Downgrades

Financial news for UTHR dated on 2011-08-24: Financial Breakfast for August 24, 2011

Financial news for UTHR dated on 2011-08-24: Deutsche Bank Downgrades United Therapeutics To Hold, \$53 PT

Financial news for UTHR dated on 2011-08-24: FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint

Financial news for UTHR dated on 2011-08-22: Oppenheimer Comments on Product Development at United Therapeutics

Financial news for UTHR dated on 2011-07-28: Biggest Gainers of the Day

Financial news for UTHR dated on 2011-07-28: United Therapeutics Reports Q2 EPS Prelim \$1.27 vs \$0.53 Est; Revenues \$183.8M vs \$180.84M Est

Financial news for UTHR dated on 2011-07-08: Earnings Ahead 07-08-2011

Financial news for UTHR dated on 2011-07-08: Calls Purchased on United Therapeutics

Financial news for UTHR dated on 2011-06-22: Oppenheimer Maintains Outperform on United Therapeutics

Financial news for UTHR dated on 2011-06-20: Pluristem Therapeutics Pops on Licensing Pact

Financial news for UTHR dated on 2011-06-07: Auriga Comments On United Therapeutics Top-Line Results

Financial news for UTHR dated on 2011-06-07: Benzinga's Top Downgrades

Financial news for UTHR dated on 2011-06-07: Jefferies Maintains Hold Rating on United Therapeutics

Financial news for UTHR dated on 2011-06-07: UPDATE: Citadel Securities Color on United Therapeutics Downgrade

Financial news for UTHR dated on 2011-06-07: Citadel Downgrades United Therapeutics To Neutral, Lowers PT To \$60

Financial news for UTHR dated on 2011-06-06: It's Inverted Hammertime! 06-06-2011

Financial news for UTHR dated on 2011-06-06: Benzinga's Top Pre-Market NASDAQ Losers

Financial news for UTHR dated on 2011-06-03: Goldman Sachs Suggests Buying Calls on United Therapeutics

Financial news for UTHR dated on 2011-06-03: Goldman Sachs Reiterates Neutral on United Therapeutics Corporation

Financial news for UTHR dated on 2011-06-01: Jefferies & Company Reports on United Therapeutics

Financial news for UTHR dated on 2011-05-20: Benzinga's Top Upgrades

Financial news for UTHR dated on 2011-05-20: UPDATE: Citadel Upgrades United Therapeutics to Add (UTHR)

Financial news for UTHR dated on 2011-05-20: Citadel Upgrades UTHR To Add, Raises PT To \$70

Financial news for UTHR dated on 2011-05-18: Collins Stewart Reports on United Therapeutics

Financial news for UTHR dated on 2011-05-11: Goldman Sachs Suggests Buying Calls on United Therapeutics (UTHR)

Financial news for UTHR dated on 2011-05-02: United Therapeutics Files \$50M Stock Securities Shelf -Bloomberg (UTHR)

Financial news for UTHR dated on 2011-04-29: Auriga Assumes Coverage Of UTHR

Financial news for UTHR dated on 2011-04-28: United Therapeutics Reports EPS of \$1.29 vs. \$0.64 Estimate; Revenues \$165.5M vs. \$178.02M Estimate (UTHR)

Financial news for UTHR dated on 2011-04-28: United Therapeutics (NASDAQ: UTHR) Reports EPS of \$1.29 vs. \$0.64 Estimate; Revenues \$165.6M vs. \$178.02M Estimate

Financial news for UTHR dated on 2011-04-26: Puts Purchased on United Therapeutics Corporation (UTHR)

Financial news for UTHR dated on 2011-04-15: Oppenheimer Maintains Overweight on United Therapeutics (UTHR)

Financial news for UTHR dated on 2011-04-14: Auriga Comments On United Therapeutics Oral Remodulin

Financial news for UTHR dated on 2011-04-01: Options Brief: United Therapeutics Corporation (UTHR)

Financial news for UTHR dated on 2011-03-21: United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial

Financial news for UTHR dated on 2011-03-18: JP Morgan Raises PT On United Therapeutics To \$85

Financial news for UTHR dated on 2011-03-09: Goldman Sachs Suggests Buying Calendar Spreads on United Therapeutics Corporation (UTHR)

Financial news for UTHR dated on 2011-03-03: Goldman Sachs Comments On Healthcare Sector (HOLX, UTHR)

Financial news for UTHR dated on 2011-02-24: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash (WCRX, VRTX, ENDP, UTHR)

Financial news for UTHR dated on 2011-02-08: Goldman Sachs Initiates Neutral Rating on Smid-Cap Biotech (UTHR, VRTX, AMLN)

Financial news for UTHR dated on 2011-01-24: Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin (ENDP, UTHR, WCRX, ALXN)

Financial news for UTHR dated on 2010-12-23: Gilead Ends Letairis Trial for IPF - Analyst Blog

Financial news for UTHR dated on 2010-12-23: Gilead Ends Letairis Trial for IPF - Analyst Blog

Financial news for UTHR dated on 2010-12-14: Pfizer Drug Withdrawn from Market - Analyst Blog

Financial news for UTHR dated on 2010-12-14: Pfizer Drug Withdrawn from Market - Analyst Blog

Financial news for UTHR dated on 2010-11-18: J.P. Morgan Raising Price Target On United Therapeutics (UTHR)

Financial news for UTHR dated on 2010-11-02: Higher Revs Drive UTHR - Analyst Blog

Financial news for UTHR dated on 2010-10-28: United Therapeutics (UTHR) - Zacks #1 Rank Top Performers

Financial news for UTHR dated on 2010-10-28: Sales Growth Sends United Therapeutics (UTHR) Shares Up 6.8%

Financial news for UTHR dated on 2010-10-28: United Therapeutics Breaking Out (UTHR)

Financial news for UTHR dated on 2010-10-27: Wedbush Changes Price Targets (UTHR, ULTI, NTGR, FFIV, CSGS, CML, CALD, UA, CRDN)

Financial news for UTHR dated on 2010-10-19: Puts Purchased on United Therapeutics Corporation (UTHR)

Financial news for UTHR dated on 2010-09-17: Options Traders Coming After Calls in UTHR

Financial news for UTHR dated on 2010-09-10: Upside Purchased on United Therapeutics (UTHR)

Financial news for UTHR dated on 2010-08-03: UTHR Up on Lower Costs, Higher Revs - Analyst Blog

Financial news for UTHR dated on 2010-06-10: J.P. Morgan Upgrades United Therapeutics To Overweight (UTHR)

Financial news for UTHR dated on 2010-06-10: Benzinga's Top Upgrades (UTHR, MBT, CHRW, OMCL)

Financial news for UTHR dated on 2010-05-20: Calls Purchased on United Therapeutics Corp.

Financial news for UTHR dated on 2010-05-18: 46 Short Setups with Stop-Losses

Financial news for UTHR dated on 2010-05-11: 27 Short Setups with Stop-Losses

Financial news for UTHR dated on 2010-05-05: 23 Short Setups with Stop-Losses

Financial news for UTHR dated on 2010-05-05: Top 5 Mid-Cap Stocks In The Healthcare Sector On The NASDAQ With The Lowest PEG Ratio (UTHR, WCRX, MYGN, ENDP, TLCR)

Financial news for UTHR dated on 2010-04-22: Trade Setups for April 22, 2010

Financial news for UTHR dated on 2010-04-21: 16 Short Setups with Stop-Losses

Financial news for UTHR dated on 2010-04-19: Top 5 Stocks In The Healthcare Sector With Lowest PEG (PDLI, PRX, MDCO, UTHR, CPIX)

Financial news for UTHR dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for UTHR dated on 2010-02-19: United Therapeutics Withdraws Application For Tyvaso Drug In EU (UTHR)

Financial news for UTHR dated on 2010-02-16: UTHR Posts Strong Q4 Revenues, As Well As Expenses

Financial news for UTHR dated on 2010-02-02: Stocks That Crossed Their 52-Week Highs (SCSS, SIRI, WRLD, UTHR, WRLS)

Financial news for UTHR dated on 2010-01-28: Benzinga's Volume Movers (FFBC, NFLX, GNTX, ALGN, UTHR)

Financial news for UTHR dated on 2010-01-14: Benzinga's Volume Movers (FMBI, MAPP, CTEL, BIDU, UTHR)

Financial news for UTHR dated on 2010-01-13: UTHR Best Biotech Stock For 2010